(PharmaNewsWire.Com, September 27, 2019 ) The growth of the market is attributed to growing aging population susceptible to coronary and peripheral artery diseases, rising PCI procedures, increasing focus of companies on clinical trials of bioresorbable stents, increasing adoption of these stents by physicians and patients, and preference for minimally invasive therapies.
The global bioresorbable stents market is expected to reach USD 417.2 Million by 2022 from USD 223.6 Million in 2016, at a CAGR of 11.5% during the forecast period 2017-2022.
Bioresorbable polymer-based stents projected to grow at the highest CAGR
Based on material, the market is segmented into bioresorbable polymer-based stents and bioresorbable metallic stents. The bioresorbable polymer-based stents segment is expected to grow at the highest CAGR during the forecast period. The growth of this market is attributed to companies’ increasing focus on developing polymeric stents and approvals being granted for polymer-based stents across various regions
Based on applications, the coronary artery diseases are expected to dominate the market in 2017
Based on application, the market is segmented into coronary artery diseases and peripheral artery diseases. In 2017, coronary artery diseases accounted for the largest share of the market. The dominance of this segment is attributed to factors such as increasing aging population prone to coronary artery diseases and the adoption of unhealthy lifestyle habits leading to increased risk of these diseases.
Europe to dominate the market during the forecast period
In 2017, Europe is expected to account for the largest share of the market. The dominance of the European market is attributed to the factors such as increasing regulatory approvals for stents which will facilitate their commercialization and rising research activities for development of bioresorbable stents. In 2017, Asia is expected to hold the second largest share of this market. Factors such as, increasing industrial development, rising disposable income, burgeoning aging population with changing lifestyle (which have increased the prevalence of CAD), and the higher prevalence of diabetes are important factors to fuel the market growth in this region.
Leading Companies The bioresorbable stents screening market is a niche market with the presence of several emerging players and few big players. Prominent players in the market include Abbott (U.S.), BIOTRONIK SE & Co. KG (Germany), REVA Medical, Inc. (U.S.), Elixir Medical Corporation (U.S.), and Kyoto Medical Planning Co., Ltd. (Japan).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
